Post-EHA 2026 AML Highlights

Featuring presentations & discussions on selected AML abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Naval Daver | Moderators: Emma Searle & Eunice Wang

The Post-EHA 2026 AML Highlights has been supported by Kura Oncology (Silver Sponsor). Supporters have no influence over the production of content.

Preliminary Agenda (subject to change)

Session 1: Prognostic stratification and molecular relapse in AML

A genetic–clinical prognostic algorithm for risk stratification in patients with relapsed/refractory acute myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation (Abstract S274) | Speaker: TBC

Venetoclax and azacitidine for molecular failure intervention as a bridge-to-transplant strategy for NPM1-mutated acute myeloid leukemia: The GIMEMA AML2521 Phase 2 trial (Abstract S128) | Speaker: Chiara Sartor

Panel discussion 

Session 2: Latest with immunotherapies and CAR T-cell therapy in AML 

Tuscany study of safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in study participants with newly diagnosed AML ineligible for induction chemotherapy (Abstract S134) | Speaker: Nikolai Podoltsev

Updated findings from the Phase 2 RIVER-81 study of romaciclib (RVU120) combined with venetoclax in acute myeloid leukemia after first-line venetoclax and hypomethylating agent failure (Abstract PF529) | Speaker: TBC

A Phase II randomized study of AK117 versus placebo in combination with venetoclax and azacitidine in previously untreated acute myeloid leukemia patients ineligible for intensive chemotherapy (Abstract S131) | Speaker: Huafeng Wang

Gilteritinib versus midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia eligible for intensive therapy: results from the Phase 3 HOVON156/AMLSG28-18/PASHA trial (Abstract LB5005) | Speaker: Marc Raaijmakers

First-in-class switchable allogeneic CAR-T therapy for CD123+ AML – results from the Phase Ia REVSTAR-123 (AVC-201-01) study (Abstract LB5007) | Speaker: TBC

Panel discussion 

Session 3: Developments in venetoclax-based combination strategies in AML

OPTI-AML: Prospective randomized Phase 2 trial of 28 versus 14 day schedule of venetoclax and azacitidine for 2 cycles in newly diagnosed genomically agnostic acute myeloid leukemia patients ≥60 years (Abstract S126) | Speaker: Joshua Zeidner

A multicenter Phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML) (Abstract S127) | Speaker: Jennifer Marvin-Peek

Triplet therapy with quizartinib, decitabine, and venetoclax in newly diagnosed and relapsed/refractory FLT3-ITD acute myeloid leukemia (Abstract PF509) | Speaker: Musa Yilmaz

Gilteritinib or ivosidenib in combination with venetoclax-based therapies for FLT3– or IDH1-mutated acute myeloid leukemia (Abstract PF565) | Speaker: Andrius Žučenka

Panel discussion 

Session 4: Advances with menin inhibitors in newly-diagnosed AML

Ziftomenib combined with intensive induction (7+3) for newly diagnosed NPM1‑M or KMT2A-R acute myeloid leukemia (AML): Long-term results from the KOMET-007 trial (Abstract S130) | Speaker: Amer Zeidan

Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: Updated Phase 1 results from SNDX-5613-0708 (Abstract PF489) | Speaker: Ibrahim Aldoss

Panel discussion 

Conclusions and webinar close